Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Public ClinicalTrials.gov record NCT00059475. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Comparison of Peptide Immunization in Patients at High Risk for Recurrence of Melanoma
Study identification
- NCT ID
- NCT00059475
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 138 participants
Conditions and interventions
Conditions
Interventions
- Glycoprotein 100 (GP100): 209-217 (210M) Drug
- Interleukin-2 (IL-2) Drug
- Montanide ISA 51 Drug
- Melanoma antigen recognized by T-cells (MART)-1: 27-35 Drug
- 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1 Drug
- melanoma antigen recognized by T-cells (MART)-1: 26-35(27L) Drug
Drug
Eligibility (public fields only)
- Age range
- 7 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2003
- Primary completion
- Apr 30, 2010
- Completion
- Apr 30, 2010
- Last update posted
- Oct 22, 2012
2003 – 2010
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Cancer Institute (NCI) | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00059475, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2012 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00059475 live on ClinicalTrials.gov.